Related Experiment Video

Updated: May 11, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

ROS kinase fusions are not common in Chinese patients with cholangiocarcinoma

Pengmin Liu1, Yajun Wu, Li Sun

  • 1Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. pengmin_123456@126.com

Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University
|May 7, 2013
PubMed
Abstract

Insights

ROS fusions were not detected in Chinese cholangiocarcinoma (CCA) patients. This study investigated ROS fusion expression in 56 CCA samples, finding none present.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cholangiocarcinoma (CCA) is a challenging malignancy with limited targeted therapies.
  • Identifying specific genetic alterations like ROS fusions could offer new therapeutic avenues.

Purpose of the Study:

  • To investigate the prevalence of ROS fusions in Chinese patients diagnosed with cholangiocarcinoma (CCA).
  • To determine if specific ROS fusion variants involving FIG, SLC34A2, or CD74 are present in CCA.

Main Methods:

  • Reverse transcription-polymerase chain reaction (RT-PCR) was used to analyze formalin-fixed, paraffin-embedded CCA tissues from 56 patients (Stage I-IV).
  • Detection focused on ROS fusions with Fused in Glioblastoma (FIG), solute carrier protein (SLC34A2), and major histocompatibility complex class II invariant chain (CD74).
  • Serpin peptidase inhibitor clade A member 1 (SERPINA1) served as the reference gene.

Main Results:

  • A total of 56 CCA samples were analyzed.
  • SERPINA1, the reference gene, was expressed in 80.4% (45/56) of evaluable samples.
  • No ROS fusions involving FIG, SLC34A2, or CD74 were detected in any of the evaluable CCA samples.

Conclusions:

  • ROS fusions are not a common genetic alteration in the studied Chinese cholangiocarcinoma (CCA) patient cohort.
  • The findings suggest that targeting ROS fusions may not be a relevant therapeutic strategy for this population.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...